JP2014525425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525425A5 JP2014525425A5 JP2014527680A JP2014527680A JP2014525425A5 JP 2014525425 A5 JP2014525425 A5 JP 2014525425A5 JP 2014527680 A JP2014527680 A JP 2014527680A JP 2014527680 A JP2014527680 A JP 2014527680A JP 2014525425 A5 JP2014525425 A5 JP 2014525425A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- halo
- alkoxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 65
- 125000003545 alkoxy group Chemical group 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- -1 cyclic ester Chemical class 0.000 claims 14
- 229910052736 halogen Chemical group 0.000 claims 14
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 150000002367 halogens Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004442 acylamino group Chemical group 0.000 claims 10
- 125000004414 alkyl thio group Chemical group 0.000 claims 10
- 239000004202 carbamide Substances 0.000 claims 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 229940124530 sulfonamide Drugs 0.000 claims 10
- 150000003456 sulfonamides Chemical group 0.000 claims 10
- 150000003573 thiols Chemical class 0.000 claims 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 8
- 125000005907 alkyl ester group Chemical group 0.000 claims 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 7
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 239000011435 rock Substances 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000003368 amide group Chemical group 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000002148 esters Chemical group 0.000 claims 3
- 150000002596 lactones Chemical class 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000029162 bladder disease Diseases 0.000 claims 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 150000003556 thioamides Chemical class 0.000 claims 2
- 208000026533 urinary bladder disease Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000005549 barrier dysfunction Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- RKJJZXDWJFJEEZ-UHFFFAOYSA-N methyl 4-[[3-[2-(aminomethyl)-5-[(3-fluoropyridin-4-yl)carbamoyl]phenyl]phenyl]carbamoyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)NC1=CC=CC(C=2C(=CC=C(C=2)C(=O)NC=2C(=CN=CC=2)F)CN)=C1 RKJJZXDWJFJEEZ-UHFFFAOYSA-N 0.000 claims 1
- JDZQFMQRFRLCBT-UHFFFAOYSA-N methyl 6-[[3-[2-(aminomethyl)-5-[(3-fluoropyridin-4-yl)carbamoyl]phenyl]phenyl]carbamoyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C(=O)NC1=CC=CC(C=2C(=CC=C(C=2)C(=O)NC=2C(=CN=CC=2)F)CN)=C1 JDZQFMQRFRLCBT-UHFFFAOYSA-N 0.000 claims 1
- ZYSZTYMDOOQBID-UHFFFAOYSA-N n-[3-[2-(aminomethyl)-5-[(3-fluoropyridin-4-yl)carbamoyl]phenyl]phenyl]-1-oxo-3h-2-benzofuran-5-carboxamide Chemical compound C1=C(C=2C=C(NC(=O)C=3C=C4COC(=O)C4=CC=3)C=CC=2)C(CN)=CC=C1C(=O)NC1=CC=NC=C1F ZYSZTYMDOOQBID-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 125000005475 oxolanyl group Chemical group 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001391 thioamide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11179491.3 | 2011-08-31 | ||
| EP11179491 | 2011-08-31 | ||
| PCT/EP2012/067016 WO2013030365A1 (en) | 2011-08-31 | 2012-08-31 | Novel rock kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014525425A JP2014525425A (ja) | 2014-09-29 |
| JP2014525425A5 true JP2014525425A5 (enExample) | 2015-10-15 |
Family
ID=46796597
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527680A Pending JP2014525425A (ja) | 2011-08-31 | 2012-08-31 | 新規のｒｏｃｋキナーゼ阻害剤 |
| JP2014527681A Withdrawn JP2014525426A (ja) | 2011-08-31 | 2012-08-31 | 新規のソフトｒｏｃｋ阻害剤 |
| JP2014527682A Withdrawn JP2014525427A (ja) | 2011-08-31 | 2012-08-31 | Ｒｏｃｋキナーゼ阻害剤としてのビフェニルカルボキサミド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527681A Withdrawn JP2014525426A (ja) | 2011-08-31 | 2012-08-31 | 新規のソフトｒｏｃｋ阻害剤 |
| JP2014527682A Withdrawn JP2014525427A (ja) | 2011-08-31 | 2012-08-31 | Ｒｏｃｋキナーゼ阻害剤としてのビフェニルカルボキサミド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9079858B2 (enExample) |
| EP (3) | EP2751079A1 (enExample) |
| JP (3) | JP2014525425A (enExample) |
| KR (2) | KR20140072879A (enExample) |
| CN (3) | CN103874682A (enExample) |
| AU (3) | AU2012300833B2 (enExample) |
| BR (3) | BR112014004545A2 (enExample) |
| CA (3) | CA2846695A1 (enExample) |
| EA (3) | EA024232B1 (enExample) |
| ES (1) | ES2560830T3 (enExample) |
| IL (2) | IL231122A0 (enExample) |
| MX (3) | MX2014002394A (enExample) |
| PT (1) | PT2751080E (enExample) |
| SG (2) | SG11201400117QA (enExample) |
| WO (3) | WO2013030366A1 (enExample) |
| ZA (3) | ZA201401417B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10842669B2 (en) * | 2008-11-13 | 2020-11-24 | Gholam A. Peyman | Ophthalmic drug delivery method |
| US9079858B2 (en) | 2011-08-31 | 2015-07-14 | Amakem Nv | Rock kinase inhibitors |
| EP2903618B1 (en) | 2012-10-05 | 2022-06-01 | Kadmon Corporation, LLC | Rho kinase inhibitors |
| EP2951172B8 (en) | 2013-01-29 | 2017-08-02 | Redx Pharma Plc | Pyridine derivatives as soft rock inhibitors |
| US10092537B2 (en) | 2013-04-15 | 2018-10-09 | Renascience Co., Ltd. | Use for PAI-1 inhibitor |
| EA028675B1 (ru) * | 2013-12-17 | 2017-12-29 | Эли Лилли Энд Компани | Соединения диметилбензойной кислоты |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US12281308B2 (en) | 2018-08-29 | 2025-04-22 | University Of Massachusetts | Inhibition of protein kinases to treat Friedreich ataxia |
| CN113801111B (zh) * | 2020-06-12 | 2025-10-17 | 上海翰森生物医药科技有限公司 | 联苯类衍生物抑制剂及其制备方法和应用 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| US20250000083A1 (en) | 2021-11-11 | 2025-01-02 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| HRP20251018T1 (hr) * | 2022-09-08 | 2025-10-24 | Redx Pharma Limited | Kruti oblici inhibitora rock |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005723A1 (fr) | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| SK283569B6 (sk) | 1993-10-01 | 2003-09-11 | Astra Aktiebolag | Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| GB0124928D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| WO2005014599A1 (en) * | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7683097B2 (en) * | 2004-05-27 | 2010-03-23 | Propharmacon Inc. | Topoisomerase inhibitors |
| CN101248046A (zh) * | 2005-07-11 | 2008-08-20 | 德福根有限公司 | 作为激酶抑制剂的酰胺衍生物 |
| WO2007006547A1 (en) | 2005-07-11 | 2007-01-18 | Devgen N.V. | Amide derivatives as kinase inhibitors |
| BRPI0615524A2 (pt) | 2005-07-11 | 2010-04-06 | Devgen Nv | derivados da amida como inibidores da quinase |
| US20070042321A1 (en) * | 2005-08-22 | 2007-02-22 | Florman Michael J | Grinder guard |
| AU2006290442B2 (en) * | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| BRPI0617548A2 (pt) * | 2005-10-13 | 2017-10-03 | Devgen Nv | Inibidores da quinase |
| CN101687819B (zh) * | 2007-08-17 | 2013-03-20 | 卫材R&D管理有限公司 | 外用剂 |
| GB201018996D0 (en) * | 2010-11-10 | 2010-12-22 | Amakem Nv | Novel ROCK inhibitors |
| EP2542528B1 (en) | 2010-03-02 | 2013-06-19 | Amakem NV | Heterocyclic amides as rock inhibitors |
| MX342310B (es) * | 2011-03-28 | 2016-09-26 | Hoffmann La Roche | Compuestos de tiazolopirimidina. |
| GB201114854D0 (en) * | 2011-08-29 | 2011-10-12 | Amakem Nv | Novel rock inhibitors |
| US9079858B2 (en) * | 2011-08-31 | 2015-07-14 | Amakem Nv | Rock kinase inhibitors |
| MX2014002965A (es) * | 2011-09-13 | 2014-07-09 | Novartis Ag | Combinaciones que comprenden un modulador del receptor de s1p. |
-
2012
- 2012-08-31 US US14/241,092 patent/US9079858B2/en not_active Expired - Fee Related
- 2012-08-31 CA CA2846695A patent/CA2846695A1/en not_active Abandoned
- 2012-08-31 EP EP12756692.5A patent/EP2751079A1/en not_active Withdrawn
- 2012-08-31 WO PCT/EP2012/067017 patent/WO2013030366A1/en not_active Ceased
- 2012-08-31 EA EA201490495A patent/EA024232B1/ru not_active IP Right Cessation
- 2012-08-31 WO PCT/EP2012/067018 patent/WO2013030367A1/en not_active Ceased
- 2012-08-31 AU AU2012300833A patent/AU2012300833B2/en not_active Expired - Fee Related
- 2012-08-31 US US14/241,096 patent/US9174939B2/en not_active Expired - Fee Related
- 2012-08-31 BR BR112014004545A patent/BR112014004545A2/pt not_active IP Right Cessation
- 2012-08-31 MX MX2014002394A patent/MX2014002394A/es unknown
- 2012-08-31 EA EA201490515A patent/EA201490515A1/ru unknown
- 2012-08-31 WO PCT/EP2012/067016 patent/WO2013030365A1/en not_active Ceased
- 2012-08-31 BR BR112014004435A patent/BR112014004435A2/pt not_active IP Right Cessation
- 2012-08-31 KR KR1020147008450A patent/KR20140072879A/ko not_active Withdrawn
- 2012-08-31 CN CN201280048511.XA patent/CN103874682A/zh active Pending
- 2012-08-31 AU AU2012300832A patent/AU2012300832A1/en not_active Abandoned
- 2012-08-31 EP EP12759666.6A patent/EP2751080B1/en not_active Not-in-force
- 2012-08-31 KR KR1020147008449A patent/KR20140079386A/ko not_active Withdrawn
- 2012-08-31 AU AU2012300834A patent/AU2012300834A1/en not_active Abandoned
- 2012-08-31 ES ES12759666.6T patent/ES2560830T3/es active Active
- 2012-08-31 EA EA201490516A patent/EA201490516A1/ru unknown
- 2012-08-31 JP JP2014527680A patent/JP2014525425A/ja active Pending
- 2012-08-31 PT PT127596666T patent/PT2751080E/pt unknown
- 2012-08-31 CN CN201280048515.8A patent/CN103874684A/zh active Pending
- 2012-08-31 CA CA2846694A patent/CA2846694A1/en not_active Abandoned
- 2012-08-31 BR BR112014004447A patent/BR112014004447A2/pt not_active IP Right Cessation
- 2012-08-31 SG SG11201400117QA patent/SG11201400117QA/en unknown
- 2012-08-31 SG SG11201400058PA patent/SG11201400058PA/en unknown
- 2012-08-31 JP JP2014527681A patent/JP2014525426A/ja not_active Withdrawn
- 2012-08-31 CN CN201280048514.3A patent/CN103874683A/zh active Pending
- 2012-08-31 US US14/241,093 patent/US9067889B2/en not_active Expired - Fee Related
- 2012-08-31 MX MX2014002395A patent/MX2014002395A/es unknown
- 2012-08-31 CA CA2846752A patent/CA2846752A1/en not_active Abandoned
- 2012-08-31 JP JP2014527682A patent/JP2014525427A/ja not_active Withdrawn
- 2012-08-31 EP EP12753983.1A patent/EP2751078A1/en not_active Withdrawn
- 2012-08-31 MX MX2014002393A patent/MX2014002393A/es unknown
-
2014
- 2014-02-24 IL IL231122A patent/IL231122A0/en unknown
- 2014-02-24 IL IL231123A patent/IL231123A0/en unknown
- 2014-02-25 ZA ZA2014/01417A patent/ZA201401417B/en unknown
- 2014-02-25 ZA ZA2014/01418A patent/ZA201401418B/en unknown
- 2014-02-25 ZA ZA2014/01416A patent/ZA201401416B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014525426A5 (enExample) | ||
| JP2014525427A5 (enExample) | ||
| JP2014512406A5 (enExample) | ||
| JP2012502986A5 (enExample) | ||
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| JP2017533968A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2015533782A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2008534511A5 (enExample) | ||
| JP2016506387A5 (enExample) | ||
| JP2011529037A5 (enExample) | ||
| JP2016519680A5 (enExample) | ||
| WO2017195216A4 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| JP2018505898A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| JP2017510643A5 (enExample) | ||
| JP2013542937A5 (enExample) | ||
| JP2013526494A5 (enExample) | ||
| JPWO2016104617A1 (ja) | キノリン誘導体 | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2017522348A5 (enExample) | ||
| CN103012378A (zh) | 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物 | |
| JP2011519956A5 (ja) | キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬 | |
| JP2008517923A5 (enExample) |